Craig-Hallum raised the firm’s price target on GeneDx (WGS) to $95 from $70 and keeps a Buy rating on the shares. The firm remains positive following a significant Q3 beat and raise and achievement of adjusted Net Income profitability several quarters sooner than it had expected.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.